Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | 1 | — | — | — | 1 |
Melanoma | D008545 | — | — | 1 | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | — | — | — | — | 1 |
Drug common name | Alfacalcidol |
INN | alfacalcidol |
Description | Alfacalcidol is a member of the class of D3 vitamins that is calciol in which the hydrogen at the 1alpha position is replaced by a hydroxy group. It is an active metabolite of cholecalciferol, which performs important functions in regulation of the calcium balance and the bone metabolism. It has a role as a bone density conservation agent. It is a member of D3 vitamins, a seco-cholestane, a hydroxycalciol and a diol. It is functionally related to a calciol. |
Classification | Small molecule |
Drug class | vitamin D analogs |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O |
PDB | — |
CAS-ID | 41294-56-8 |
RxCUI | — |
ChEMBL ID | CHEMBL1601669 |
ChEBI ID | 31186 |
PubChem CID | 5282181 |
DrugBank | DB01436 |
UNII ID | URQ2517572 (ChemIDplus, GSRS) |